• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".他克莫司谷浓度的患者内变异性可能并非病因，而是合并症的一个间接参数：关于“降低慢性肾脏病风险的他克莫司最佳水平以及患者内变异性对肝移植后慢性肾脏病和终末期肾病发展的影响”的社论
Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.
2
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内药物浓度变异性对慢性肾脏病和终末期肾病发生发展的影响。
Clin Mol Hepatol. 2025 Jan;31(1):131-146. doi: 10.3350/cmh.2024.0451. Epub 2024 Oct 2.
3
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".肝移植后他克莫司水平及慢性肾脏病和终末期肾病风险的变异性：致编辑的信，主题为“降低慢性肾脏病风险的最佳他克莫司水平以及肝移植后患者内变异性对慢性肾脏病和终末期肾病发展的影响”
Clin Mol Hepatol. 2025 Apr;31(2):e137-e139. doi: 10.3350/cmh.2024.1159. Epub 2025 Jan 9.
4
Correspondence to editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".致关于“降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内变异性对慢性肾脏病和终末期肾病发展的影响”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e161-e162. doi: 10.3350/cmh.2025.0121. Epub 2025 Feb 13.
5
Correspondence to letter to the editor on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".致编辑的信，内容涉及“降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内变异性对慢性肾脏病和终末期肾病发展的影响”
Clin Mol Hepatol. 2025 Apr;31(2):e212-e214. doi: 10.3350/cmh.2025.0100. Epub 2025 Feb 10.
6
High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation.肝移植后他克莫司暴露的个体内变异性高与免疫介导的移植物损伤无关。
Transplantation. 2019 Nov;103(11):2329-2337. doi: 10.1097/TP.0000000000002680.
7
Patterns in Tacrolimus Variability and Association with Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.他克莫司变异性模式及其与儿科肾移植受者供体特异性抗体形成的关系。
Clin J Am Soc Nephrol. 2022 Aug;17(8):1194-1203. doi: 10.2215/CJN.16421221. Epub 2022 Jul 26.
8
Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.他克莫司谷浓度变异性与非裔美国肾移植患者的差异
Transplantation. 2017 Dec;101(12):2931-2938. doi: 10.1097/TP.0000000000001840.
9
Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.他克莫司血药浓度的个体内变异性不能预测心脏移植后心脏移植血管病变的发生。
Exp Clin Transplant. 2018 Jun;16(3):326-332. doi: 10.6002/ect.2016.0366. Epub 2017 Sep 30.
10
Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.他克莫司谷浓度变异性可预测肾移植后同种异体肾长期存活情况。
J Nephrol. 2016 Apr;29(2):269-276. doi: 10.1007/s40620-015-0230-0. Epub 2015 Sep 15.

引用本文的文献

1
Correspondence to editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".致关于“降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内变异性对慢性肾脏病和终末期肾病发展的影响”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e161-e162. doi: 10.3350/cmh.2025.0121. Epub 2025 Feb 13.

本文引用的文献

1
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内药物浓度变异性对慢性肾脏病和终末期肾病发生发展的影响。
Clin Mol Hepatol. 2025 Jan;31(1):131-146. doi: 10.3350/cmh.2024.0451. Epub 2024 Oct 2.
2
Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis.影响他克莫司患者内变异的因素和干预措施：系统评价和荟萃分析。
Transplant Rev (Orlando). 2024 Dec;38(4):100878. doi: 10.1016/j.trre.2024.100878. Epub 2024 Sep 7.
3
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.亚太肝病学会肝脏移植临床实践指南。
Hepatol Int. 2024 Apr;18(2):299-383. doi: 10.1007/s12072-023-10629-3. Epub 2024 Feb 28.
4
Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.替诺福韦酯富马酸二吡呋酯和恩替卡韦在肝移植患者中的肾脏安全性：一项全国性韩国注册研究。
Hepatol Int. 2022 Jun;16(3):537-544. doi: 10.1007/s12072-022-10320-z. Epub 2022 Apr 23.
5
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry.韩国肝移植的结局：韩国移植登记处的发生率和危险因素。
Clin Mol Hepatol. 2021 Jul;27(3):451-462. doi: 10.3350/cmh.2020.0292. Epub 2021 Feb 2.
6
Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective.实体器官移植中他克莫司的患者内变异：多器官视角。
Pharmacotherapy. 2021 Jan;41(1):103-118. doi: 10.1002/phar.2480. Epub 2020 Dec 24.
7
Effect of on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients.关于[未提及内容]对稳定期肝移植患者每日一次他克莫司转换的影响。
J Clin Med. 2020 Sep 8;9(9):2897. doi: 10.3390/jcm9092897.
8
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.患者内他克莫司浓度变异性高可预测肾移植受者慢性组织学病变的加速进展。
Am J Transplant. 2016 Oct;16(10):2954-2963. doi: 10.1111/ajt.13803. Epub 2016 Apr 21.
9
Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.肝移植后慢性肾脏病及相关死亡率——一项使用实测肾小球滤过率的时间依赖性分析
J Hepatol. 2014 Aug;61(2):286-92. doi: 10.1016/j.jhep.2014.03.034. Epub 2014 Apr 5.
10
Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis.他克莫司谷浓度、肝移植中的排斥反应和肾功能损害：系统评价和荟萃分析。
Am J Transplant. 2012 Oct;12(10):2797-814. doi: 10.1111/j.1600-6143.2012.04140.x.

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".

作者信息

Kim Jongman

机构信息

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.

DOI:10.3350/cmh.2025.0076
PMID:39849960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12016652/
Abstract
摘要